Surge in Adenomyosis Disorders is projected to drive the Demand for Adenomyosis Drugs Market

A study published in 2020, in a series of 200 hysterectomies, showed that the incidence of adenomyosis would increase from 31% to 38.5%, contributing a larger share in reproductive disorders in females. In January 2019, a retrospective review of a consecutive cohort of 710 premenopausal women with adenomyosis who underwent a hysterectomy, it was found that 343 (48.3%), 158 (22.3%), 129 (18.2%) and 80 (11.3%) patients, respectively, had adenomyosis alone, adenomyosis and endometriosis, adenomyosis and uterine fibroids, and all three conditions combined. The high prevalence of adenomyosis disorders raises the demand for the early detection and diagnosis via utilizing the latest technology, thereby propelling the growth of the global adenomyosis drugs market. Thus, the high prevalence of adenomyosis cases is expected to be a driver for the market's growth.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-adenomyosis-drugs-market

Data Bridge Market Research analyses that the adenomyosis drugs market is expected to grow at a CAGR of 5.9% in the forecast period of 2022 to 2029 and is expected to reach USD 4, 66,791.75 thousand by 2029. The development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women also undergoing conservative treatments, identifying different phenotypes of the disease. After some attempts of histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium: intrinsic, extrinsic, intramural, and indeterminate.

Increase Demand for Disease-Specific Drug Treatment is expected to drive the Market's Growth Rate

According to pathogenic mechanisms, several medical hormonal and non-hormonal treatments are used off-label to manage pain and bleeding and to improve fertility outcomes. The use of GnRHa is indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis, and the highest pregnancy rate is reported in those undergoing frozen embryo transfer after GnRHa pre-treatment. In contrast, the use of GnRHa for pain and bleeding should be considered only for short-term treatment because of menopausal effects. The levonorgestrel-releasing intrauterine system (LNG-IUS) is also an effective, reversible, and long-term treatment used successfully to treat adenomyosis. The results show that it reduces menstrual bleeding, pain, and uterine volume and has an overall satisfaction of 72%, which is why they are largely adopted. However, new drugs, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelet therapy, are under development for the treatment of adenomyosis.

Report Scope and Market Segmentation

Segment Analysis:

The global adenomyosis drugs market is categorized into six notable segments based on type, treatment, patient type, dosage form, end user and distribution channel.

• On the basis of type, the adenomyosis drugs market is segmented into diffuse, nodular, sclerotic, adult cystic and others. In 2022, diffuse segment is dominating in the adenomyosis drugs market growing with the highest CAGR of 6.4%

The diffuse segment is dominating in the adenomyosis drugs market growing with the highest CAGR of 6.4%

In 2022, diffuse segment is dominating in the adenomyosis drugs market growing with the highest CAGR of 6.4% in the forecast period of 2022 to 2029 owing to the high incidence of this type as compared to the rest which make it more common with high rate of prevalence.

• On the basis of treatment, the adenomyosis drugs market is segmented into hormone medications and anti-inflammatory drugs. In 2022, hormonal medications segment is expected to dominate in the adenomyosis drugs market growing with the highest CAGR of 6.2% in the forecast period of 2022 to 2029 because this treatment is used to reduce the size of the lesion size and is a potentially a safest option for the retention of fertility.
• On the basis of patient type, the adenomyosis drugs market is segmented into adult, geriatric and adolescence. In 2022, adult segment is dominating in the adenomyosis drugs market growing with the highest CAGR of 6.1% in the forecast period of 2022 to 2029 owing to the high incidence of this among this patient pool especially among menopausal and post-menopausal women.
• On the basis of dosage form, the adenomyosis drugs market is segmented into parenteral, oral and others. In 2022, oral segment is dominating in the adenomyosis drugs market growing with the highest CAGR of 6.1% in the forecast period of 2022 to 2029 owing to the ease of administration and most of the drugs are available in this form.
• On the basis of end user, the adenomyosis drugs market is segmented into hospitals, clinics, specialty center, home healthcare, ambulatory centers and others. In 2022, hospital segment is expected to dominate the adenomyosis drugs market growing with the highest CAGR of 7.1%

The hospital segment is expected to dominate the adenomyosis drugs market growing with the highest CAGR of 7.1%

In 2022, hospital segment is expected to dominate the adenomyosis drugs market growing with the highest CAGR of 7.1% in the forecast period of 2022 to 2029 this segment because of presence of a large professional's portfolio available for giving the proper treatment. Moreover, cost-effective and high quality diagnostic care and services in safe healthcare environment are provided.

• On the basis of distribution channel, the adenomyosis drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2022, hospital pharmacies segment is expected to dominate the adenomyosis drugs market growing with the highest CAGR of 6.6% in the forecast period of 2022 to 2029 as they are the primary source of procurement of medication and therapies by healthcare organizations. Procuring products through hospital pharmacies is highly cost effective and convenient for healthcare providers.

Major Players

Data Bridge Market Research recognizes the following companies as the major adenomyosis drugs market players in adenomyosis drugs market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (U.S.), Bayer AG (Germany), Perrigo Company plc (Ireland), Tolmar Pharmaceuticals, Inc. (U.S.), Reckitt Benckiser Group PLC (U.K.), Sun Pharmaceutical Industries Ltd. (India), Assertio Therapeutics, Inc. (U.S.).

Market Development

• In October 2021, Debiopharm, a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, announced the Indonesian launch of triptorelin for the treatment of women with Gynecological disorders, particularly adenomyosis, and its related diseases
• In September 2019, Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF have been awarded a three-year US$2.07 million (AU$3.05 million) grant to determine the cause of adenomyosis and the physiological processes associated with the diseases
• In October 2020, Bayer AG acquired Asklepios BioPharmaceutical, a company focused on innovating new solutions targeting neuromuscular, central nervous system, respiratory, women health, among others. This initiative allowed the company to boost up the company's product portfolio and to fulfil the unmet patient's demands that has accelerated the company's overall growth
• In January 2020, Novartis AG announced that it had acquired of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Sandoz acquired all of the shares in Aspen Japan K.K. and associated assets held by AGI. The acquired portfolio complements existing Sandoz portfolio and consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands

Regional Analysis

Geographically, the countries covered in the adenomyosis drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in adenomyosis drugs market during the forecast period

North America dominated the adenomyosis drugs market owing to the large number of pharmaceutical companies. North America will continue to dominate the adenomyosis drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the increasing healthcare expenditure.

Asia-Pacific is estimated to be the fastest growing region in adenomyosis drugs market

Asia-Pacific is expected to grow during the forecast period due to the huge network of suppliers in this region. In addition, the growing presence of major market players and rising disposable income are expected to propel the market's growth rate in this region.

For more detailed information about the adenomyosis drugs market report, click here – https://www.databridgemarketresearch.com/reports/global-adenomyosis-drugs-market